• Io Therapeutics Inc., of Santa Ana, Calf., presented preclinical data for its compound IRX4204 in animal models of Alzheimer's disease at the 6th Neurodegenerative Conditions Research and Development conference in San Francisco. The results showed attenuation of cognitive deterioration.
